JPMorgan
http://www.jpmorgan.comJPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $1.5 trillion and operations in more than 50 countries. The firm is a leader in investment banking, financial services for consumers, small business and commercial banking, financial transaction processing, asset management, and private equity.
-
Big Lots (BIG) Downgraded at Both ThinkEquity and Piper Jaffray
-
Big Lots (BIG) Cut to Underperform at JPMorgan Following Oct. Retail Sales Numbers
-
Notable Analyst Rating Changes 06/22: VRX, LNCR, MAT, ARBA Upgraded; BVF, BIG, WAG, NOV Downgraded
-
J.P. Morgan Downgrades Big Lots (BIG) to Neutral
-
J.P. Morgan Upgrades Big Lots (BIG) to Overweight
-
Notable Analyst Rating Changes 01/20: KELYA, CBS, SHPGY, SWIR, IBM Upgraded; TSCO, BIG, AAP, VRS, CPO Downgraded
-
J.P. Morgan Downgrades Big Lots (BIG) to Neutral
-
Notable Analyst Rating Changes 10/01: AA, CHU, BIG, BHI, OMX, FRPT Upgraded; SKS, RVSN, KBH, NVDA, PMCS, A Downgraded
-
JP Morgan Upgrades Big Lots (BIG) to Overweight
-
Notable Analyst Rating Changes 5/27: RF, PFG, LVS, SLP Upgraded; CTXS, BIG, CTCM Downgraded
-
David Moenning's Daily State of the Markets: 5/27
-
Big Lots (BIG): Downgraded at JP Morgan - cautious ahead of numbers
-
J.P. Morgan Downgrades Big Lots (BIG) to Neutral
-
Notable Analyst Rating Changes 4/3: RIMM, DVN, ICE, ELN Upgraded; DIS, BMY, MON, AKAM Downgraded
-
David Moenning's Daily State of the Markets: 3/11
-
JP Morgan Upgrades Big Lots (BIG) to Overweight
-
Morning Movers 3/4: GE (GE) Sinks Lower, Big Lots (BIG) Up on Strong Results
-
David Moenning's Daily State of the Markets: 12/05
-
David Moenning's Daily State of the Markets: 9/16
-
J.P. Morgan Downgrades Big Lots (BIG) to Neutral
-
David Moenning's Daily State of the Markets: 5/29
-
Notable Analyst Rating Changes 4/28: LCC, BIG, MRVL Upgraded; MOT, KSS, AIG, BEBE Downgraded
-
J.P. Morgan Upgrades Big Lots (BIG) to Overweight
-
Pre-Open Movers 3/5: Packeteer (PKTR) Up On Buyout Offer, Big Lots (BIG) Up on Results; PDL BioPharma (PDLI) Sinks on Results/No Sale
